Genetics and Molecular Biology · 2014 · 23 citations · 22 references
Life SciencesNeurologyEnzymologyMedical GeneticsNeuropathologyEnzyme DeficienciesGenetic DisordersLysosomal DysfunctionLysosomal Storage DisordersTherapeutic EnzymesBetween-group ComparisonCohort Study InvestigationEnzyme Deficiency DisordersEnzyme Replacement TherapyInherited Metabolic Enzyme DisordersLysosomal Enzyme DeficiencyOverall MortalityRespiratory Infection Mortality
Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder caused by deficiency of alpha-L-iduronidase. Few clinical trials have assessed the effect of enzyme replacement therapy (ERT) for this condition. We conducted an exploratory, open-label, non-randomized, multicenter cohort study of patients with MPS I. Data were collected from questionnaires completed by attending physicians at the time of diagnosis (T1; n = 34) and at a median time of 2.5 years later (T2; n = 24/34). The 24 patients for whom data were available at T2 were allocated into groups: A, no ERT (9 patients; median age at T1 = 36 months; 6 with severe phenotype); B, on ERT (15 patients; median age at T1 = 33 months; 4 with severe phenotype). For all variables in which there was no between-group difference at baseline, a delta of ≥ ± 20% was considered clinically relevant. The following clinically relevant differences were identified in group B in T2: lower rates of mortality and reported hospitalization for respiratory infection; lower frequency of hepatosplenomegaly; increased reported rates of obstructive sleep apnea syndrome and hearing loss; and stabilization of gibbus deformity. These changes could be due to the effect of ERT or of other therapies which have also been found more frequently in group B. Our findings suggest MPS I patients on ERT also receive a better overall care. ERT may have a positive effect on respiratory morbidity and overall mortality in patients with MPS I. Additional studies focusing on these outcomes and on other therapies should be performed.
22
The metabolic and molecular bases of inherited disease
Ying-Tsong Chen · Medical Entomology and Zoology · 2001 · 6.9K citations
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
Emil Kakkis, Joseph Muenzer, George E. Tiller et al. · New England Journal of Medicine · 2001 · 675 citations · Full text
J. E. Wraith, L. Clarke, Michael Beck et al. · The Journal of Pediatrics · 2004 · 546 citations
Mucopolysaccharidosis I: Management and Treatment Guidelines
Joseph Muenzer, J. E. Wraith, L. Clarke · PEDIATRICS · 2008 · 460 citations
Medicine, Hematology, Pediatrics +10